Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2012-08-05

AUTHORS

Patrick A. Ott, Richard D. Carvajal, Neeta Pandit-Taskar, Achim A. Jungbluth, Eric W. Hoffman, Bor-Wen Wu, John S. Bomalaski, Ralph Venhaus, Linda Pan, Lloyd J. Old, Anna C. Pavlick, Jedd D. Wolchok

ABSTRACT

Background Arginine deiminase (ADI) is an enzyme that degrades arginine, an amino acid that is important for growth and development of normal and neoplastic cells. Melanoma cells are auxotrophic for arginine, because they lack argininosuccinatesynthetase (ASS), a key enzyme required for the synthesis of arginine. Patients and methods Patients with advanced melanoma were treated with 40, 80 or 160 IU/m2 ADI-PEG 20 i.m. weekly. Primary endpoints were toxicity and tumor response, secondary endpoints included metabolic response by 18FDG-PET, pharmacodynamic (PD) effects upon circulating arginine levels, and argininosuccinate synthetase tumor expression by immunohistochemistry. Results 31 previously treated patients were enrolled. The main toxicities were grade 1 and 2 adverse events including injection site pain, rash, and fatigue. No objective responses were seen. Nine patients achieved stable disease (SD), with 2 of these durable for >6 months. Four of the 9 patients with SD had uveal melanoma. PD analysis showed complete plasma arginine depletion in 30/31 patients by day 8. Mean plasma levels of ADI-PEG 20 correlated inversely with ADI-PEG 20 antibody levels. Immunohistochemical ASS expression analysis in tumor tissue was negative in 24 patients, whereas 5 patients had <5 % cells positive. Conclusions ADI-PEG 20 is well tolerated in advanced melanoma patients and leads to consistent, but transient, arginine depletion. Although no RECIST responses were observed, the encouraging rate of SD in uveal melanoma patients indicates that it may be worthwhile to evaluate ADI-PEG 20 in this melanoma subgroup. More... »

PAGES

425-434

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10637-012-9862-2

DOI

http://dx.doi.org/10.1007/s10637-012-9862-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1034251924

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22864522


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cohort Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hydrolases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunoenzyme Techniques", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Maximum Tolerated Dose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Melanoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Polyethylene Glycols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Skin Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tissue Distribution", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Uveal Neoplasms", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Melanoma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, 02215-5450, Boston, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.65499.37", 
          "name": [
            "Department of Medical Oncology, New York University School of Medicine, New York, NY, USA", 
            "Melanoma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, 02215-5450, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ott", 
        "givenName": "Patrick A.", 
        "id": "sg:person.01003444252.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01003444252.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Carvajal", 
        "givenName": "Richard D.", 
        "id": "sg:person.0726366600.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726366600.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pandit-Taskar", 
        "givenName": "Neeta", 
        "id": "sg:person.0753173312.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753173312.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ludwig Institute for Cancer Research, Branch at Memorial Sloan-Kettering Cancer Center, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.1052.6", 
          "name": [
            "Ludwig Institute for Cancer Research, Branch at Memorial Sloan-Kettering Cancer Center, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jungbluth", 
        "givenName": "Achim A.", 
        "id": "sg:person.0770572636.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0770572636.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ludwig Institute for Cancer Research, Branch at Memorial Sloan-Kettering Cancer Center, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.1052.6", 
          "name": [
            "Ludwig Institute for Cancer Research, Branch at Memorial Sloan-Kettering Cancer Center, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hoffman", 
        "givenName": "Eric W.", 
        "id": "sg:person.01075270460.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075270460.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Polaris Pharmaceuticals, San Diego, CA, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Polaris Pharmaceuticals, San Diego, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wu", 
        "givenName": "Bor-Wen", 
        "id": "sg:person.01304452567.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304452567.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Polaris Pharmaceuticals, San Diego, CA, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Polaris Pharmaceuticals, San Diego, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bomalaski", 
        "givenName": "John S.", 
        "id": "sg:person.01217735242.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217735242.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ludwig Institute for Cancer Research, Branch at Memorial Sloan-Kettering Cancer Center, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.1052.6", 
          "name": [
            "Ludwig Institute for Cancer Research, Branch at Memorial Sloan-Kettering Cancer Center, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Venhaus", 
        "givenName": "Ralph", 
        "id": "sg:person.01033465263.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033465263.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ludwig Institute for Cancer Research, Branch at Memorial Sloan-Kettering Cancer Center, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.1052.6", 
          "name": [
            "Ludwig Institute for Cancer Research, Branch at Memorial Sloan-Kettering Cancer Center, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pan", 
        "givenName": "Linda", 
        "id": "sg:person.01043324025.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01043324025.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ludwig Institute for Cancer Research, Branch at Memorial Sloan-Kettering Cancer Center, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.1052.6", 
          "name": [
            "Ludwig Institute for Cancer Research, Branch at Memorial Sloan-Kettering Cancer Center, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Old", 
        "givenName": "Lloyd J.", 
        "id": "sg:person.01054231444.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01054231444.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, New York University School of Medicine, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.137628.9", 
          "name": [
            "Department of Medical Oncology, New York University School of Medicine, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pavlick", 
        "givenName": "Anna C.", 
        "id": "sg:person.01276612250.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01276612250.59"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ludwig Institute for Cancer Research, Branch at Memorial Sloan-Kettering Cancer Center, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.1052.6", 
          "name": [
            "Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA", 
            "Ludwig Institute for Cancer Research, Branch at Memorial Sloan-Kettering Cancer Center, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wolchok", 
        "givenName": "Jedd D.", 
        "id": "sg:person.0645565266.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645565266.33"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.bjc.6605856", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027168571", 
          "https://doi.org/10.1038/sj.bjc.6605856"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.2012.106", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031699199", 
          "https://doi.org/10.1038/bjc.2012.106"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6600681", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040582181", 
          "https://doi.org/10.1038/sj.bjc.6600681"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-08-05", 
    "datePublishedReg": "2012-08-05", 
    "description": "Background Arginine deiminase (ADI) is an enzyme that degrades arginine, an amino acid that is important for growth and development of normal and neoplastic cells. Melanoma cells are auxotrophic for arginine, because they lack argininosuccinatesynthetase (ASS), a key enzyme required for the synthesis of arginine. Patients and methods Patients with advanced melanoma were treated with 40, 80 or 160\u00a0IU/m2 ADI-PEG 20 i.m. weekly. Primary endpoints were toxicity and tumor response, secondary endpoints included metabolic response by 18FDG-PET, pharmacodynamic (PD) effects upon circulating arginine levels, and argininosuccinate synthetase tumor expression by immunohistochemistry. Results 31 previously treated patients were enrolled. The main toxicities were grade 1 and 2 adverse events including injection site pain, rash, and fatigue. No objective responses were seen. Nine patients achieved stable disease (SD), with 2 of these durable for >6\u00a0months. Four of the 9 patients with SD had uveal melanoma. PD analysis showed complete plasma arginine depletion in 30/31 patients by day 8. Mean plasma levels of ADI-PEG 20 correlated inversely with ADI-PEG 20 antibody levels. Immunohistochemical ASS expression analysis in tumor tissue was negative in 24 patients, whereas 5 patients had <5\u00a0% cells positive. Conclusions ADI-PEG 20 is well tolerated in advanced melanoma patients and leads to consistent, but transient, arginine depletion. Although no RECIST responses were observed, the encouraging rate of SD in uveal melanoma patients indicates that it may be worthwhile to evaluate ADI-PEG 20 in this melanoma subgroup.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10637-012-9862-2", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2438793", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "31"
      }
    ], 
    "keywords": [
      "ADI-PEG 20", 
      "stable disease", 
      "advanced melanoma", 
      "melanoma patients", 
      "phase I/II study", 
      "arginine depletion", 
      "injection site pain", 
      "advanced melanoma patients", 
      "uveal melanoma patients", 
      "arginine deiminase", 
      "RECIST response", 
      "primary endpoint", 
      "secondary endpoints", 
      "main toxicity", 
      "site pain", 
      "Methods Patients", 
      "adverse events", 
      "objective response", 
      "II study", 
      "antibody levels", 
      "pharmacodynamic effects", 
      "tumor expression", 
      "tumor response", 
      "plasma levels", 
      "uveal melanoma", 
      "patients", 
      "neoplastic cells", 
      "encouraging rates", 
      "day 8", 
      "arginine levels", 
      "tumor tissue", 
      "grade 1", 
      "melanoma cells", 
      "melanoma", 
      "metabolic response", 
      "melanoma subgroups", 
      "PD analysis", 
      "Results 31", 
      "endpoint", 
      "synthesis of arginine", 
      "cells", 
      "toxicity", 
      "arginine", 
      "response", 
      "rash", 
      "pain", 
      "deiminase", 
      "immunohistochemistry", 
      "key enzyme", 
      "levels", 
      "disease", 
      "expression analysis", 
      "months", 
      "depletion", 
      "subgroups", 
      "amino acids", 
      "tissue", 
      "enzyme", 
      "expression", 
      "fatigue", 
      "study", 
      "rate", 
      "events", 
      "effect", 
      "analysis", 
      "acid", 
      "i.", 
      "development", 
      "growth", 
      "synthesis"
    ], 
    "name": "Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma", 
    "pagination": "425-434", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1034251924"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10637-012-9862-2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22864522"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10637-012-9862-2", 
      "https://app.dimensions.ai/details/publication/pub.1034251924"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:29", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_554.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10637-012-9862-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-012-9862-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-012-9862-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-012-9862-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-012-9862-2'


 

This table displays all metadata directly associated to this object as RDF triples.

320 TRIPLES      21 PREDICATES      119 URIs      108 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10637-012-9862-2 schema:about N04fcd68cd700423aa450ab8e7e066c0f
2 N1455524abc8540089cb60586e17fb896
3 N2a80038fc88f49d7be4fcf249eb51956
4 N2ed8d3c33e35426a90ecdc25da32f6d7
5 N3286a7aeb1b543e5906e0e4526cf3e5e
6 N3913d92d0add4bbb81a28b1bf3eadb16
7 N424db0dd809b464f9fde7138558bacff
8 N4983f8c8e2754624900ddb1389c2f776
9 N52557c8458754001b535841fbffc59e6
10 N5c9f693f0eb94f64aaeefc054de2da64
11 N83c6e1e203fd466297cc53b79391537f
12 N9a59151d86574fbdbcd146faf37a75a3
13 N9e3989dd43b940c7bd2c6624a6223042
14 Naac64f27c58a4ffaac5ff71b5bf64562
15 Nafe9227af5c746c2971fa9be1e6bf244
16 Nd300203dc7c74583b42d177c9d7ee75a
17 Nd518652b198f4b8fa8777a307091fe04
18 Nd956583ef623418ab8fd44a15344d4a7
19 Ne7e7ee3a035c48b58a0ac7f66c853eba
20 Nf8a8a1b483ab420faf56aded6d3fd844
21 Nfc2e7306c6bd402e8b7ef573e181e11f
22 anzsrc-for:11
23 anzsrc-for:1112
24 schema:author N0888c6e17ec544b9b4fc9c616125c1ee
25 schema:citation sg:pub.10.1038/bjc.2012.106
26 sg:pub.10.1038/sj.bjc.6600681
27 sg:pub.10.1038/sj.bjc.6605856
28 schema:datePublished 2012-08-05
29 schema:datePublishedReg 2012-08-05
30 schema:description Background Arginine deiminase (ADI) is an enzyme that degrades arginine, an amino acid that is important for growth and development of normal and neoplastic cells. Melanoma cells are auxotrophic for arginine, because they lack argininosuccinatesynthetase (ASS), a key enzyme required for the synthesis of arginine. Patients and methods Patients with advanced melanoma were treated with 40, 80 or 160 IU/m2 ADI-PEG 20 i.m. weekly. Primary endpoints were toxicity and tumor response, secondary endpoints included metabolic response by 18FDG-PET, pharmacodynamic (PD) effects upon circulating arginine levels, and argininosuccinate synthetase tumor expression by immunohistochemistry. Results 31 previously treated patients were enrolled. The main toxicities were grade 1 and 2 adverse events including injection site pain, rash, and fatigue. No objective responses were seen. Nine patients achieved stable disease (SD), with 2 of these durable for >6 months. Four of the 9 patients with SD had uveal melanoma. PD analysis showed complete plasma arginine depletion in 30/31 patients by day 8. Mean plasma levels of ADI-PEG 20 correlated inversely with ADI-PEG 20 antibody levels. Immunohistochemical ASS expression analysis in tumor tissue was negative in 24 patients, whereas 5 patients had <5 % cells positive. Conclusions ADI-PEG 20 is well tolerated in advanced melanoma patients and leads to consistent, but transient, arginine depletion. Although no RECIST responses were observed, the encouraging rate of SD in uveal melanoma patients indicates that it may be worthwhile to evaluate ADI-PEG 20 in this melanoma subgroup.
31 schema:genre article
32 schema:isAccessibleForFree true
33 schema:isPartOf N6103d343fa4d43069b448f09dff7d7e8
34 Nf91e236377924ae59ae11ae31c650303
35 sg:journal.1094201
36 schema:keywords ADI-PEG 20
37 II study
38 Methods Patients
39 PD analysis
40 RECIST response
41 Results 31
42 acid
43 advanced melanoma
44 advanced melanoma patients
45 adverse events
46 amino acids
47 analysis
48 antibody levels
49 arginine
50 arginine deiminase
51 arginine depletion
52 arginine levels
53 cells
54 day 8
55 deiminase
56 depletion
57 development
58 disease
59 effect
60 encouraging rates
61 endpoint
62 enzyme
63 events
64 expression
65 expression analysis
66 fatigue
67 grade 1
68 growth
69 i.
70 immunohistochemistry
71 injection site pain
72 key enzyme
73 levels
74 main toxicity
75 melanoma
76 melanoma cells
77 melanoma patients
78 melanoma subgroups
79 metabolic response
80 months
81 neoplastic cells
82 objective response
83 pain
84 patients
85 pharmacodynamic effects
86 phase I/II study
87 plasma levels
88 primary endpoint
89 rash
90 rate
91 response
92 secondary endpoints
93 site pain
94 stable disease
95 study
96 subgroups
97 synthesis
98 synthesis of arginine
99 tissue
100 toxicity
101 tumor expression
102 tumor response
103 tumor tissue
104 uveal melanoma
105 uveal melanoma patients
106 schema:name Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma
107 schema:pagination 425-434
108 schema:productId N038851b959d34d15a881135671699160
109 N10035abb15e242b688c78021770be8a1
110 Nb0577e65965d415f98d8f17267d8556d
111 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034251924
112 https://doi.org/10.1007/s10637-012-9862-2
113 schema:sdDatePublished 2022-12-01T06:29
114 schema:sdLicense https://scigraph.springernature.com/explorer/license/
115 schema:sdPublisher N4741b908fd814022b4bc623e0d07f93b
116 schema:url https://doi.org/10.1007/s10637-012-9862-2
117 sgo:license sg:explorer/license/
118 sgo:sdDataset articles
119 rdf:type schema:ScholarlyArticle
120 N038851b959d34d15a881135671699160 schema:name dimensions_id
121 schema:value pub.1034251924
122 rdf:type schema:PropertyValue
123 N04fcd68cd700423aa450ab8e7e066c0f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Aged
125 rdf:type schema:DefinedTerm
126 N0888c6e17ec544b9b4fc9c616125c1ee rdf:first sg:person.01003444252.49
127 rdf:rest N22a7550aff94409190853441c4e73974
128 N10035abb15e242b688c78021770be8a1 schema:name pubmed_id
129 schema:value 22864522
130 rdf:type schema:PropertyValue
131 N1455524abc8540089cb60586e17fb896 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Female
133 rdf:type schema:DefinedTerm
134 N22a7550aff94409190853441c4e73974 rdf:first sg:person.0726366600.25
135 rdf:rest N8a9b3431b9444359b20e37fffe8c7e6e
136 N2a80038fc88f49d7be4fcf249eb51956 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Survival Rate
138 rdf:type schema:DefinedTerm
139 N2ed8d3c33e35426a90ecdc25da32f6d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Middle Aged
141 rdf:type schema:DefinedTerm
142 N3286a7aeb1b543e5906e0e4526cf3e5e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Hydrolases
144 rdf:type schema:DefinedTerm
145 N3913d92d0add4bbb81a28b1bf3eadb16 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Humans
147 rdf:type schema:DefinedTerm
148 N424db0dd809b464f9fde7138558bacff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Prognosis
150 rdf:type schema:DefinedTerm
151 N4741b908fd814022b4bc623e0d07f93b schema:name Springer Nature - SN SciGraph project
152 rdf:type schema:Organization
153 N4983f8c8e2754624900ddb1389c2f776 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Skin Neoplasms
155 rdf:type schema:DefinedTerm
156 N52557c8458754001b535841fbffc59e6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Male
158 rdf:type schema:DefinedTerm
159 N5c9f693f0eb94f64aaeefc054de2da64 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Melanoma
161 rdf:type schema:DefinedTerm
162 N5ed016d00aaf4de8ba414567ec121c3c rdf:first sg:person.01054231444.61
163 rdf:rest Nd51735ca2861439b8102483be7d86612
164 N6103d343fa4d43069b448f09dff7d7e8 schema:issueNumber 2
165 rdf:type schema:PublicationIssue
166 N83c6e1e203fd466297cc53b79391537f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Cohort Studies
168 rdf:type schema:DefinedTerm
169 N895e5429d9d0477ba2cc41c6a2fb984d rdf:first sg:person.01043324025.19
170 rdf:rest N5ed016d00aaf4de8ba414567ec121c3c
171 N8a9b3431b9444359b20e37fffe8c7e6e rdf:first sg:person.0753173312.35
172 rdf:rest N9904b978c2374d45a966957974e49d64
173 N9904b978c2374d45a966957974e49d64 rdf:first sg:person.0770572636.19
174 rdf:rest Nb2d53f823f874346900f394b8022390d
175 N9a59151d86574fbdbcd146faf37a75a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Neoplasm Staging
177 rdf:type schema:DefinedTerm
178 N9d90591cf0ee4118ada47a2fbde20ff9 rdf:first sg:person.0645565266.33
179 rdf:rest rdf:nil
180 N9e3989dd43b940c7bd2c6624a6223042 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Follow-Up Studies
182 rdf:type schema:DefinedTerm
183 Na5e942d557b64f53bf79d8e2b165d707 rdf:first sg:person.01304452567.08
184 rdf:rest Neab4d531e6d7478098e12f2864b08b34
185 Naac64f27c58a4ffaac5ff71b5bf64562 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Immunoenzyme Techniques
187 rdf:type schema:DefinedTerm
188 Nafe9227af5c746c2971fa9be1e6bf244 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Aged, 80 and over
190 rdf:type schema:DefinedTerm
191 Nb0577e65965d415f98d8f17267d8556d schema:name doi
192 schema:value 10.1007/s10637-012-9862-2
193 rdf:type schema:PropertyValue
194 Nb2d53f823f874346900f394b8022390d rdf:first sg:person.01075270460.74
195 rdf:rest Na5e942d557b64f53bf79d8e2b165d707
196 Nd0a8d30916a6488abb33979bb52999ee rdf:first sg:person.01033465263.03
197 rdf:rest N895e5429d9d0477ba2cc41c6a2fb984d
198 Nd300203dc7c74583b42d177c9d7ee75a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Adult
200 rdf:type schema:DefinedTerm
201 Nd51735ca2861439b8102483be7d86612 rdf:first sg:person.01276612250.59
202 rdf:rest N9d90591cf0ee4118ada47a2fbde20ff9
203 Nd518652b198f4b8fa8777a307091fe04 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Polyethylene Glycols
205 rdf:type schema:DefinedTerm
206 Nd956583ef623418ab8fd44a15344d4a7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name Dose-Response Relationship, Drug
208 rdf:type schema:DefinedTerm
209 Ne7e7ee3a035c48b58a0ac7f66c853eba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
210 schema:name Maximum Tolerated Dose
211 rdf:type schema:DefinedTerm
212 Neab4d531e6d7478098e12f2864b08b34 rdf:first sg:person.01217735242.46
213 rdf:rest Nd0a8d30916a6488abb33979bb52999ee
214 Nf8a8a1b483ab420faf56aded6d3fd844 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
215 schema:name Uveal Neoplasms
216 rdf:type schema:DefinedTerm
217 Nf91e236377924ae59ae11ae31c650303 schema:volumeNumber 31
218 rdf:type schema:PublicationVolume
219 Nfc2e7306c6bd402e8b7ef573e181e11f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
220 schema:name Tissue Distribution
221 rdf:type schema:DefinedTerm
222 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
223 schema:name Medical and Health Sciences
224 rdf:type schema:DefinedTerm
225 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
226 schema:name Oncology and Carcinogenesis
227 rdf:type schema:DefinedTerm
228 sg:grant.2438793 http://pending.schema.org/fundedItem sg:pub.10.1007/s10637-012-9862-2
229 rdf:type schema:MonetaryGrant
230 sg:journal.1094201 schema:issn 0167-6997
231 1573-0646
232 schema:name Investigational New Drugs
233 schema:publisher Springer Nature
234 rdf:type schema:Periodical
235 sg:person.01003444252.49 schema:affiliation grid-institutes:grid.65499.37
236 schema:familyName Ott
237 schema:givenName Patrick A.
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01003444252.49
239 rdf:type schema:Person
240 sg:person.01033465263.03 schema:affiliation grid-institutes:grid.1052.6
241 schema:familyName Venhaus
242 schema:givenName Ralph
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033465263.03
244 rdf:type schema:Person
245 sg:person.01043324025.19 schema:affiliation grid-institutes:grid.1052.6
246 schema:familyName Pan
247 schema:givenName Linda
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01043324025.19
249 rdf:type schema:Person
250 sg:person.01054231444.61 schema:affiliation grid-institutes:grid.1052.6
251 schema:familyName Old
252 schema:givenName Lloyd J.
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01054231444.61
254 rdf:type schema:Person
255 sg:person.01075270460.74 schema:affiliation grid-institutes:grid.1052.6
256 schema:familyName Hoffman
257 schema:givenName Eric W.
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075270460.74
259 rdf:type schema:Person
260 sg:person.01217735242.46 schema:affiliation grid-institutes:None
261 schema:familyName Bomalaski
262 schema:givenName John S.
263 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217735242.46
264 rdf:type schema:Person
265 sg:person.01276612250.59 schema:affiliation grid-institutes:grid.137628.9
266 schema:familyName Pavlick
267 schema:givenName Anna C.
268 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01276612250.59
269 rdf:type schema:Person
270 sg:person.01304452567.08 schema:affiliation grid-institutes:None
271 schema:familyName Wu
272 schema:givenName Bor-Wen
273 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304452567.08
274 rdf:type schema:Person
275 sg:person.0645565266.33 schema:affiliation grid-institutes:grid.1052.6
276 schema:familyName Wolchok
277 schema:givenName Jedd D.
278 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645565266.33
279 rdf:type schema:Person
280 sg:person.0726366600.25 schema:affiliation grid-institutes:grid.51462.34
281 schema:familyName Carvajal
282 schema:givenName Richard D.
283 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726366600.25
284 rdf:type schema:Person
285 sg:person.0753173312.35 schema:affiliation grid-institutes:grid.51462.34
286 schema:familyName Pandit-Taskar
287 schema:givenName Neeta
288 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753173312.35
289 rdf:type schema:Person
290 sg:person.0770572636.19 schema:affiliation grid-institutes:grid.1052.6
291 schema:familyName Jungbluth
292 schema:givenName Achim A.
293 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0770572636.19
294 rdf:type schema:Person
295 sg:pub.10.1038/bjc.2012.106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031699199
296 https://doi.org/10.1038/bjc.2012.106
297 rdf:type schema:CreativeWork
298 sg:pub.10.1038/sj.bjc.6600681 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040582181
299 https://doi.org/10.1038/sj.bjc.6600681
300 rdf:type schema:CreativeWork
301 sg:pub.10.1038/sj.bjc.6605856 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027168571
302 https://doi.org/10.1038/sj.bjc.6605856
303 rdf:type schema:CreativeWork
304 grid-institutes:None schema:alternateName Polaris Pharmaceuticals, San Diego, CA, USA
305 schema:name Polaris Pharmaceuticals, San Diego, CA, USA
306 rdf:type schema:Organization
307 grid-institutes:grid.1052.6 schema:alternateName Ludwig Institute for Cancer Research, Branch at Memorial Sloan-Kettering Cancer Center, New York, NY, USA
308 schema:name Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
309 Ludwig Institute for Cancer Research, Branch at Memorial Sloan-Kettering Cancer Center, New York, NY, USA
310 rdf:type schema:Organization
311 grid-institutes:grid.137628.9 schema:alternateName Department of Medical Oncology, New York University School of Medicine, New York, NY, USA
312 schema:name Department of Medical Oncology, New York University School of Medicine, New York, NY, USA
313 rdf:type schema:Organization
314 grid-institutes:grid.51462.34 schema:alternateName Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
315 schema:name Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
316 rdf:type schema:Organization
317 grid-institutes:grid.65499.37 schema:alternateName Melanoma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, 02215-5450, Boston, MA, USA
318 schema:name Department of Medical Oncology, New York University School of Medicine, New York, NY, USA
319 Melanoma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, 02215-5450, Boston, MA, USA
320 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...